References
- Brahm AJ, Hegele RA. Chylomicronaemia–current diagnosis and future therapies. Nat Rev Endocrinol. 2015;11(6):352–362.
- Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res. 2011;52(2):189–206.
- Nawaz H, Koutroumpakis E, Easler J, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol. 2015;110(10):1497–1503.
- Chang MC, Su CH, Sun MS, et al. Etiology of acute pancreatitis–a multi-center study in Taiwan. Hepato-Gastroenterology. 2003;50(53):1655–1657.
- Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol. 1995;90(12):2134–2139.
- Valdivielso P, Ramirez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014;25(8):689–694.
- Gaudet D, de Wal J, Tremblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl. 2010;11(1):55–60.
- Rashid N, Sharma PP, Scott RD, et al. Severe hypertriglyceridemia and factors associated with acute pancreatitis in an integrated health care system. J Clin Lipidol. 2016;10(4):880–890.
- Murphy MJ, Sheng X, MacDonald TM, et al. Hypertriglyceridemia and acute pancreatitis. JAMA Intern Med. 2013;173(2):162–164.
- Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969–2989.
- Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med. 2006;354(20):2142–2150.
- Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118(4):547–563.
- Veniant MM, Beigneux AP, Bensadoun A, et al. Lipoprotein size and susceptibility to atherosclerosis–insights from genetically modified mouse models. Curr Drug Targets. 2008;9(3):174–189.
- Burnett HA JR, Hegele RA. Familial lipoprotein lipase deficiency. In Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle: University of Washington; 1999 Oct 12. [Updated 2017 Jun 22].
- Pouwels ED, Blom DJ, Firth JC, et al. Severe hypertriglyceridaemia as a result of familial chylomicronaemia: the Cape Town experience. S Afr Med J. 2008;98(2):105–108.
- Familial lipoprotein lipase deficiency. Genetics Home References; [cited 2017 Sept 1]. 2017. Available from: https://ghr.nlm.nih.gov/condition/familial-lipoprotein-lipase-deficiency.
- Davidson M, Stevenson M, Hsieh A, et al. The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. Expert Rev Cardiovasc Ther. 2017;15(5):415–423.
- Weiss AJ, Elixhauser A. Overview of hospital stays in the United States, 2012: HCUP Statistical Brief #180. October 2014 Rockville (MD): Agency for HealthcareResearch and Quality. [cited 2017 Sep 1]. Available from: http://www.hcup-us.ahrq.gov/nisoverview.jsp.
- Bureau of Labor Statistics. bls.gov [Internet]. Washington (DC): United States Department of Labor; [cited 2017 Feb 15]. Available from: https://www.bls.gov/bls/employment.htm
- Mitchell RJ, Bates P. Measuring health-related productivity loss. Popul Health Manag. 2011;14(2):93–98.
- Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200–2206.
- Living with FCS. The FCS Foundation. [cited 2017 Sep 1]. Available from: https://www.livingwithFCS.org.
- Living with LPLD. LPLD Alliance. [cited 2017 Sep 1]. Available from: www.lpldalliance.org.
- National Organization for Rare Disorders. [cited 2017 Sep 1]. Available from: https://rarediseases.org.